Biomarker for anti-tumor therapy

The invention relates to the field of biomarkers useful in monitoring anti-tumor therapy response, in particular response to immune checkpoint inhibitors. In particular, the biomarker identified herein is a plexin of the A-class, in particular plexin A4. More in particular expression of a plexin of the A-class in circulating T-cells, in particular circulating CTLs, is an early non-invasive biomarker for response to anti-tumor therapy. Methods of using this biomarker as well as kits relying on this biomarker are part of the invention.

Octrooi-publicatienummer: WO2022063957

Jaar aanvraag: 2021

Jaar toekenning: 2023

Jaar van publicatie: 2022

Status: Aangevraagd

Technologiedomeinen: Analyse van biologische materialen, Biotechnologie

Gevalideerd voor IOF-sleutel: Ja

Toegewezen aan: Associatie KULeuven